38P - Predictive effect of Cytokines in Non-Small Cell Lung Cancer (38P)

Date 08 December 2017
Event ESMO Immuno-Oncology Congress 2017
Session Lunch & Poster Display session
Topics Neuroendocrine Cancers
Presenter Rudolf Huber
Citation Annals of Oncology (2017) 28 (suppl_11): xi6-xi29. 10.1093/annonc/mdx711
Authors R.M. Huber1, J. Stump1, S. Reu2, Y. Jiang1, C. Karches3, J.S. Gosálvez3, J. Neumann4, S. Kobold3, A. Tufman1, R. Hatz5, H. Winter6
  • 1Division Of Respiratory Medicine And Thoracic Oncology, Ludwig Maximilian University of Munich and Thoracic Oncology Centre Munich, Germany; Comprehensive Pneumology Center (CPC) and Member of the German Center for Lung Research (DZL, CPC-M), 80336 - Munich/DE
  • 2Institute Of Pathology, University of Munich; Comprehensive Pneumology Center (CPC) and Member of the German Center for Lung Research (DZL, CPC-M), Munich/DE
  • 3Center For Integrated Protein Science Munich (cipsm) And Division Of Clinical Pharmacology, Ludwig Maximilian University of Munich, Munich/DE
  • 4Institute Of Pathology, University of Munich, Munich/DE
  • 5Department Of Thoracic Surgery, Munich University Hospital Großhadern; Asklepios Clinic Munich-Gauting, Germany; Comprehensive Pneumology Center (CPC) and Member of the German Center for Lung Research (DZL, CPC-M), Munich/DE
  • 6Department Of Thoracic Surgery, University of Heidelberg, Heidelberg/DE



In non-small cell lung cancer (NSCLC) TNM staging remains gold standard for prognostic assessment and therapy decisions. Nevertheless, stage-specific outcomes vary significantly, indicating a need for additional prognosticators. Lymphocytic infiltrates in NSCLC patients are associated with a significant increase in disease-free and overall survival (OS). In our project we want to assess the role of cytokines using the example of interleukin-22 (IL-22) and interleukin-17 (IL-17) at the invasive margin (IM) and tumor center (CT) and link these results with prognosis, survival, therapy response and recurrence.


Tissue microarrays (TMAs) were generated from formalin-fixed paraffin embedded tissue (FFPE) of more than 200 curatively resected patients with stage IA-IIIA NSCLC. TMAs included each 3 cores from CT and IM, selected from areas with most dense lymphocytic infiltrates. IL-22 and IL-17 expression was analyzed by immunohistochemistry (double-staining: IL-22, CD3 resp. IL-17, CD3).


In NSCLC IL-17 is known to promote metastasis. Interestingly we found that in squamous cell carcinoma (SCC) a high IL-17 expression is associated with longer survival, both in IM and CT. For adenocarcinoma the same tendency is visible, but not that pronounced. The IL-17 CT/IM ratio seems to be significant for adenocarcinoma: A high ratio corresponds to a prolonged survival. In SCC a similar tendency is visible, but not statistically significant.

For IL-22 a high CT/IM ratio is cleary linked with longer OS in adenocarcinoma, this cannot be seen in SCC.


Assessment of IL-17 and IL-22 performed on “hot-spots” NSCLC shows a clear correlation with clinical outcome: High IL-17 expression status seems to be linked to prolonged survival, similar results can be seen for IL-22 in adenocarcinoma. We validate these findings in a larger cohort of patients and correlate them with immune infiltrates.

Clinical trial identification

Legal entity responsible for the study

Prof. Dr. R. M Huber




All authors have declared no conflicts of interest.